title: Effect of phenobarbital on hepatic eicosanoid concentrations in rats.
abstract: Phenobarbital is an efficacious tumor-promoting agent in the liver. Studies using inhibitors of eicosanoid synthesis have suggested that eicosanoids are important in the promotion of hepatocarcinogenesis by phenobarbital. We therefore hypothesized that hepatic eicosanoid concentrations are altered following phenobarbital administration. Male Sprague-Dawley rats were fed one of four levels of phenobarbital (0, 0.02, 0.05, and 0.1%). Eight rats from each of the four groups were killed after 10, 24, and 44 days for determination of liver weight and for preparation of microsomes. No significant difference was found among rat weights; however, liver weights were significantly higher in rats fed phenobarbital. Assay of benzyloxyresorufin-O-dealkylase activity showed that cytochromes P-450 2B1 and 2B2 were induced in response to phenobarbital administration. Prostaglandin E2 concentrations were found to be significantly decreased by phenobarbital treatment after 10 and 24 days, but not after 44 days. Prostaglandin F2 alpha levels were decreased only by the lowest dietary phenobarbital concentration. Hepatic concentrations of leukotriene C4 were decreased significantly at 10 days and at 44 days (only for the group administered the highest percentage concentration of phenobarbital), but not at 24 days. These results show that the investigated eicosanoids are generally slightly decreased by phenobarbital administration. Elevated eicosanoid levels therefore do not appear to be necessary for the promoting activity of phenobarbital.
authors.affiliation: Graduate Center for Toxicology, University of Kentucky, Lexington 40506, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: Peebles
authors.forename: H P
authors.initials: HP
authors.lastname: Glauert
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001189:Aryl Hydrocarbon Hydroxylases; D019362:Cytochrome P-450 CYP2B1 / Q000032:analysis; D003577:Cytochrome P-450 Enzyme System / Q000032:analysis; D015237:Dinoprost / Q000032:analysis; D015232:Dinoprostone / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D015777:Eicosanoids / Q000032:analysis*; D006993:Hypnotics and Sedatives / Q000633:toxicity*; D017997:Leukotriene C4 / Q000032:analysis; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects* / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D010634:Phenobarbital / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013250:Steroid Hydroxylases / Q000032:analysis; D013997:Time Factors
chemical_list: D015777:Eicosanoids; D006993:Hypnotics and Sedatives; D017997:Leukotriene C4; D003577:Cytochrome P-450 Enzyme System; D015237:Dinoprost; D013250:Steroid Hydroxylases; D001189:Aryl Hydrocarbon Hydroxylases; D019362:Cytochrome P-450 CYP2B1; C025619:steroid 16-beta-hydroxylase; D015232:Dinoprostone; D010634:Phenobarbital